Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Research

The role of trust and hope in antipsychotic medication reviews between GPs and service users a realist review

Authors: L. M. Grünwald, C. Duddy, R. Byng, N. Crellin, J. Moncrieff

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

Increasing number of service users diagnosed with schizophrenia and psychosis are being discharged from specialist secondary care services to primary care, many of whom are prescribed long-term antipsychotics. It is unclear if General Practitioners (GPs) have the confidence and experience to appropriately review and adjust doses of antipsychotic medication without secondary care support.

Aim

To explore barriers and facilitators of conducting antipsychotic medication reviews in primary care for individuals with no specialist mental health input.

Design & setting

Realist review in general practice settings.

Method

A realist review has been conducted to synthesise evidence on antipsychotic medication reviews conducted in primary care with service users diagnosed with schizophrenia or psychosis. Following initial scoping searches and discussions with stakeholders, a systematic search and iterative secondary searches were conducted. Articles were systematically screened and analysed to develop a realist programme theory explaining the contexts (C) and mechanisms (M) which facilitate or prevent antipsychotic medication reviews (O) in primary care settings, and the potential outcomes of medication reviews.

Results

Meaningful Antipsychotic medication reviews may not occur for individuals with only primary care medical input. Several, often mutually reinforcing, mechanisms have been identified as potential barriers to conducting such reviews, including low expectations of recovery for people with severe mental illness, a perceived lack of capability to understand and participate in medication reviews, linked with a lack of information shared in appointments between GPs and Service Users, perceived risk and uncertainty regarding antipsychotic medication and illness trajectory.

Conclusions

The review identified reciprocal and reinforcing stereotypes affecting both GPs and service users. Possible mechanisms to counteract these barriers are discussed, including realistic expectations of medication, and the need for increased information sharing and trust between GPs and service users.

Available only for authorised users

Burns T, Kendrick T. The primary care of patients with schizophrenia: a search for good practice. Br J Gen Pract. 1997;47(421):515–20.PubMedPubMedCentral

Kendrick B, Freeling S. Provision of care to general practice patients with disabling long-term mental illness: a survey in 16 practices. Br J Gen Pract. 1994;44(384):301–5.

Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in service provision for people with severe mental illness in the United Kingdom. PLoS One. 2012;7(5):e36468.

Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry. Wiley; 2018.

Jones R, Major B, Fear C. Schizophrenia in a primary care setting. Curr Psychiatry Rep. 2015;17(10):31–4.CrossRef

Raynsford J, Dada C, Stansfield D, Cullen T. Impact of a specialist mental health pharmacy team on medicines optimisation in primary care for patients on a severe mental illness register: a pilot study. Eur J Hosp Pharm. 2020;27(1):31–5. https://doi.org/10.1136/ejhpharm-2018-001514.CrossRefPubMed

Mortimer AM. Atypical antipsychotics as first-line treatments for schizophrenia. Dis Manag Heal Outcomes. 2004;12(3):169–79. https://doi.org/10.2165/00115677-200412030-00003.CrossRef

Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry [Internet] 2004;6(Suppl 2):3–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16001094%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC487011

Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(20):2137.

10.

Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609–16. https://doi.org/10.1001/archgenpsychiatry.2011.2.CrossRefPubMed

11.

Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med. 2010;40(9):1409–22. https://doi.org/10.1017/S0033291709992297.CrossRefPubMed

12.

Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680–91. https://doi.org/10.1016/j.neubiorev.2013.06.001.CrossRefPubMedPubMedCentral

13.

Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - an observational 9-year follow-up study. Schizophr Res [Internet]. 2014;158(1–3):134–41. Available from:. https://doi.org/10.1016/j.schres.2014.06.035.CrossRef

14.

Murray RM, Quattrone D, Natesan S, Van Os J, Nordentoft M, Howes O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics. Br J Psychiatry. 2016;209(5):361–5. https://doi.org/10.1192/bjp.bp.116.182683.CrossRefPubMed

15.

Morrison AP, Hutton P, Shiers D, Turkington D. Antipsychotics: is it time to introduce patient choice? Br J Psychiatry. 2012;201(2):83–4. https://doi.org/10.1192/bjp.bp.112.112110.CrossRefPubMed

16.

Gupta S, Cahill JD. A prescription for “deprescribing” in psychiatry. Psychiatr Serv. 2016;67(8):904–7. https://doi.org/10.1176/appi.ps.201500359.CrossRefPubMed

17.

Pawson R. Evidence-based policy: a realist perspective: Sage; 2006. https://doi.org/10.4135/9781849209120.

18.

Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol - realist and meta-narrative evidence synthesis: evolving standards (RAMESES). BMC Med Res Methodol. 2011;11(1). https://doi.org/10.1186/1471-2288-11-115.

19.

Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (realist and meta-narrative evidence syntheses – evolving standards) project. Heal Serv Deliv Res [Internet]. 2014;2(30):1–252. Available from:. https://doi.org/10.3310/hsdr02300.CrossRef

20.

Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review-a new method of systematic review designed for complex policy interventions. Journal of health services research & policy. 2005 Jul;10(1_suppl):21–34.

21.

Moncrieff J, Lewis G, Freemantle N, Johnson S, Barnes TR, Morant N, et al. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (research into antipsychotic discontinuation and reduction). BMJ Open. 2019;9(11):e030912. https://doi.org/10.1136/bmjopen-2019-030912.CrossRefPubMedPubMedCentral

22.

Booth A, Briscoe S, Wright JM. The “realist search”: a systematic scoping review of current practice and reporting. Res Synth Methods. 2020;11(1):14–35. https://doi.org/10.1002/jrsm.1386.CrossRefPubMed

23.

Corrigan PW. Mental health stigma as social attribution. Clin Psychology Sci Pract. 2000;7(1):48–67. https://doi.org/10.1093/clipsy.7.1.48.CrossRef

24.

Francis-Graham S, Ekeke NA, Nelson CA, Lee TY, El Haj S, Rhodes T, et al. Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review. BMC Health Serv Res. 2019;19(1):1–8.CrossRef

25.

Jagosh J, Pluye P, Macaulay AC, Salsberg J, Henderson J, Sirett E, et al. Assessing the outcomes of participatory research: protocol for identifying, selecting, appraising and synthesizing the literature for realist review. Implement Sci. 2011;6(1):1–8.CrossRef

26.

Hong Q, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal Tool (MMAT) Version 2018: User guide. McGill [Internet]. 2018;1–11. Available from: http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf%0Ahttp://mixedmethodsappraisaltoolpublic.pbworks.com/.

27.

CASP. Critical appraisal skills Programme. CASP Systematic Review Critical Appraisal Checklist. 2018;2018:1–4 Available from: https://casp-uk.net/wp-content/uploads/2018/01/CASP-Systematic-Review-Checklist_2018.pdf.

28.

Baker E, Gwernan-Jones R, Britten N, Cox M, McCabe C, Retzer A, et al. Refining a model of collaborative care for people with a diagnosis of bipolar, schizophrenia or other psychoses in England: a qualitative formative evaluation. BMC Psychiatry. 2019;19(1):1–17.CrossRef

29.

Boardman GH, McCann TV, Clark E. Accessing health care professionals about antipsychotic medication related concerns. Issues Ment Health Nurs. 2008;29(7):739–54. https://doi.org/10.1080/01612840802129178.CrossRefPubMed

30.

Rasmussen J. Improving practice. Drugs Context [Internet] 2006;2(13):589–599. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L44842250%5Cnhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=17451981&id=doi:&atitle=Improving+practice&stitle=Drugs+Context&title=Drugs+in+Context&volume=2&issue=13&spage=589&epage

31.

Toews J, Lockyer J, Addington D, McDougall G, Ward R, Simpson E. Improving the management of patients with schizophrenia in primary care: assessing learning needs as a first step. Can J Psychiatr. 1996;41(10):617–22. https://doi.org/10.1177/070674379604101003.CrossRef

32.

Lester HE, Tritter JQ, Sorohan H. Patients’ and health professionals’ views on primary care for people with serious mental illness: focus group study. Br Med J. 2005;330(7500):1122–6. https://doi.org/10.1136/bmj.38440.418426.8F.CrossRef

33.

Feeney L, Mooney M. Atypical antipsychotic monitoring: a survey of patient knowledge and experience. Ir J Psychol Med. 2006;23(3):100–2. https://doi.org/10.1017/S0790966700009721.CrossRefPubMed

34.

Lambert TJR, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust. 2009;190(4 SUPPL):2–5.

35.

Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol [Internet]. 2014;24(4):499–509. Available from:. https://doi.org/10.1016/j.euroneuro.2014.01.014.CrossRef

36.

Millar E, Garland C, Ross F, Kendrick T, Burns T. Practice nurses and the care of patients receiving depot neuroleptic treatment: views on training, confidence and use of structured assessment. J Adv Nurs [Internet]. 1999;29(6):1454–61. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=107209307&site=ehost-live. https://doi.org/10.1046/j.1365-2648.1999.01033.x.CrossRef

37.

Morant N, Kaminskiy E, Ramon S. Shared decision making for psychiatric medication management: beyond the micro-social. Health Expect. 2016;19(5):1002–14. https://doi.org/10.1111/hex.12392.CrossRefPubMed

38.

Rogers A, Campbell S, Gask L, Sheaff R, Marshall M, Halliwell S, et al. Some National Service Frameworks are more equal than others: implementing clinical governance for mental health in primary care groups and trusts. J Ment Health. 2002;11(2):199–212. https://doi.org/10.1080/2-09638230020023589.CrossRef

39.

Royal College of Psychiatrists. Mental illness : stigmatisation and discrimination within the medical. 2001. 1–40 p.

40.

Hustig HH, Norrie PD. Managing schizophrenia in the community. Med J Aust. 1998;168(4):186–91. https://doi.org/10.5694/j.1326-5377.1998.tb126782.x.CrossRefPubMed

41.

Dixon RP, Roberts LM, Lawrie S, Jones LA, Humphreys MS. Medical students’ attitudes to psychiatric illness in primary care. Med Educ. 2008;42(11):1080–7. https://doi.org/10.1111/j.1365-2923.2008.03183.x.CrossRefPubMed

42.

Schulze B. Stigma and mental health professionals: a review of the evidence on an intricate relationship. Int Rev Psychiatry. 2007;19(2):137–55. https://doi.org/10.1080/09540260701278929.CrossRefPubMed

43.

Le Geyt G, Awenat Y, Tai S, Haddock G. Personal accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res. 2017;27(4):559–72. https://doi.org/10.1177/1049732316634047.CrossRefPubMed

44.

Lambert TJR, Chapman LH, Bell S, Carr N, D’Emden M, Elsom S, et al. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust. 2004;181(10):544–8. https://doi.org/10.5694/j.1326-5377.2004.tb06443.x.CrossRefPubMed

45.

Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand [Internet]. 1997;95(6):464–468. Available from: http://ovidsp.ovid.com/ovidweb.cgi? T=JS&PAGE=reference&D=emed4&NEWS=N&AN=1997193220.

46.

Tranulis C, Goff D, Henderson DC, Freudenreich O. Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatr Serv. 2011;62(8):888–92. https://doi.org/10.1176/ps.62.8.pss6208_0888.

47.

Pilgrim D, Rogers A. Mental health service users’ views of medical practitioners. J Interprof Care. 1993;7(2):167–76. https://doi.org/10.3109/13561829309014978.CrossRef

48.

Kendrick T, Burns T, Freeling P. Randomised controlled trial of teaching general practitioners to carry out structured assessments of their long term mentally ill patients. Bmj. 1995;311(6997):93–7. https://doi.org/10.1136/bmj.311.6997.93.CrossRefPubMedPubMedCentral

49.

Mortimer A., Shepherd C., Rymer M, Burrows A. Primary care use of antipsychotic drugs: An audit and intervention study. Ann Gen Psychiatry. 2005;4(1).

50.

Galon P, Heifner GC. Engagement in primary care treatment by persons with severe and persistent mental illness. Arch Psychiatr Nurs. 2012;26(4):272–84. https://doi.org/10.1016/j.apnu.2011.12.001.CrossRefPubMed

51.

Donlon PT. The schizophrenias: medical diagnosis and treatment by the family physician. J Fam Pract. 1978;6(1):71–82.PubMed

52.

Morrison P, Meehan T, Stomski NJ. Living with antipsychotic medication side-effects: the experience of Australian mental health consumers. Int J Ment Health Nurs. 2015;24(3):253–61. https://doi.org/10.1111/inm.12110.CrossRefPubMed

53.

Lawrie M, McNeill D, Chrystie R, et al. General practitioners’ attitudes to psychiatric and medical illness. Psychol Med. 1998;28(6):1463–7. https://doi.org/10.1017/S0033291798007004.CrossRefPubMed

54.

Lester H, Tritter JQ, England E. Satisfaction with primary care: the perspectives of people with schizophrenia. Fam Pract. 2003;20(5):508–13. https://doi.org/10.1093/fampra/cmg502.CrossRefPubMed

55.

Johnson DAW, Rasmussen JGC. Professional attitudes in the UK towards neuroleptic maintenance therapy in schizophrenia. Psychiatr Bull. 1997;21(7):394–7. https://doi.org/10.1192/pb.21.7.394.CrossRef

56.

Jones LR, Knopke HJ. Educating Family Physicians To Care for the Chronically Mentally Ill. 1987;24(2):177–83.

57.

Viron M, Baggett T, Hill M, Freudenreich O. Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. Am J Med [Internet]. 2012;125(3):223–30. Available from:. https://doi.org/10.1016/j.amjmed.2011.05.002.CrossRef

58.

Katschnig H. Psychiatry’s contribution to the public stereotype of schizophrenia: historical considerations. J Eval Clin Pract. 2018;24(5):1093–100. https://doi.org/10.1111/jep.13011.CrossRefPubMedPubMedCentral

59.

Magliano L, Strino A, Punzo R, Acone R, Affuso G, Read J. Effects of the diagnostic label “schizophrenia”, actively used or passively accepted, on general practitioners’ views of this disorder. Int J Soc Psychiatry. 2017;63(3):224–34. https://doi.org/10.1177/0020764017695353.CrossRefPubMed

60.

Maidment ID, Brown P, Calnan M. An exploratory study of the role of trust in medication management within mental health services. Int J Clin Pharm. 2011;33(4):614–20. https://doi.org/10.1007/s11096-011-9510-5.CrossRefPubMed

61.

Delman J, Clark JA, Eisen SV, Parker VA. Facilitators and barriers to the active participation of clients with serious mental illnesses in medication decision making: the perceptions of young adult clients. J Behav Health Serv Res. 2015;42(2):238–53. https://doi.org/10.1007/s11414-014-9431-x.CrossRefPubMed

62.

Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L. Why and how people decide to stop taking prescribed psychiatric medication: exploring the subjective process of choice. Psychiatr Rehabil J. 2009;33(1):38–46. https://doi.org/10.2975/33.1.2009.38.46.CrossRefPubMed

63.

Salomon C, Hamilton B. “All roads lead to medication?” qualitative responses from an Australian first-person survey of antipsychotic discontinuation. Psychiatr Rehabil J. 2013;36(3):160–5. https://doi.org/10.1037/prj0000001.CrossRefPubMed

64.

Rogers A, Day JC, Williams B, Randall F, Wood P, Healy D. The meaning and management of neuroleptic medication: A study of patients with a diagnosis of schizophrenia. Soc Sci Med [Internet]. 1998;47(9):1313–23 Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=28444745.CrossRef

65.

Seale C, Chaplin R, Lelliott P, Quirk A. Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations. Soc Sci Med. 2007;65(4):698–711. https://doi.org/10.1016/j.socscimed.2007.03.047.CrossRefPubMed

66.

Britten N, Riley R, Morgan M. Resisting psychotropic medicines: a synthesis of qualitative studies of medicine-taking. Adv Psychiatr Treat. 2010;16(3):207–18. https://doi.org/10.1192/apt.bp.107.005165.CrossRef

67.

Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–47. https://doi.org/10.1038/sj.mp.4002136.CrossRefPubMed

68.

Usher K. Taking neuroleptic medications as the treatment for schizophrenia: a phenomenological study. Aust N Z J Ment Health Nurs [Internet] 2001;10(3):145–155. Available from: 10.1046/j.1440-0979.2001.00205.x/abstract%5Cnhttp://onlinelibrary.wiley.com/doi/10.1046/j.1440-0979.2001.00205.x/full%5Cnhttp://onlinelibrary.wiley.com/doi/10.1046/j.1440-0979.2001.00205.x/pdf

69.

Carrick R, Mitchell A, Powell RA, Lloyd K. The quest for well-being: a qualitative study of the experience of taking antipsychotic medication. Psychol Psychother Theory Res Pract. 2004;77(1):19–33. https://doi.org/10.1348/147608304322874236.CrossRef

70.

Crawford MJ, Jayakumar S, Lemmey SJ, Zalewska K, Patel MX, Cooper SJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry. 2014;205(6):473–7. https://doi.org/10.1192/bjp.bp.113.142521.CrossRefPubMed

71.

Aref-Adib G, O’Hanlon P, Fullarton K, Morant N, Sommerlad A, Johnson S, et al. A qualitative study of online mental health information seeking behaviour by those with psychosis. BMC Psychiatry [Internet]. 2016;16(1):1–10 Available from: https://doi.org/10.1186/s12888-016-0952-0.CrossRef

72.

Mitchell AJ, Selmes T. Why don’t patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat. 2007;13(5):336–46. https://doi.org/10.1192/apt.bp.106.003194.CrossRef

73.

Schachter D, Kleinman I, Williams JI. Informed consent for antipsychotic medication: Do family physicians document obtaining it? Can Fam Physician. 1999;45(JUN):1502–8.PubMedPubMedCentral

74.

Younas M, Bradley E, Holmes N, Sud D, Maidment ID. Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. Int J Clin Pharm. 2016;38(5):1191–9. https://doi.org/10.1007/s11096-016-0352-z.CrossRefPubMedPubMedCentral

75.

Oud MJ, Schuling J, Slooff CJ, Groenier KH, Dekker JH, Meyboom-De JB. Care for patients with severe mental illness: the general practitioner’s role perspective. BMC Fam Pract. 2009;10:1–8.CrossRef

76.

McDonell MG, Kaufman EA, Srebnik DS, Ciechanowski PS, Ries RK. Barriers to metabolic Care for Adults with serious mental illness: provider perspectives. Int J Psychiatry Med. 2011;41(4):379–87. https://doi.org/10.2190/PM.41.4.g.CrossRefPubMed

77.

Corrigan PW, Kosyluk KA. Erasing the stigma: where science meets advocacy. Basic Appl Soc Psych. 2013;35(1):131–40. https://doi.org/10.1080/01973533.2012.746598.CrossRef

78.

The Schizophrenia Commission. The Abandoned Illness: A Report by the Schizophrenia Commission [Internet]. 2012. London: Rethink Mental Illness. Available from: http://www.healthpromoting.com/sites/default/files/fastingsp2011.pdf

79.

Dillner L. Mental health law obsolete, says inquiry. BMJ [Internet]. 1995;310(6973):145–6. Available from:. https://doi.org/10.1136/bmj.310.6973.145a.CrossRef

80.

Carr VJ, Lewin TJ, Barnard RE, Walton JM, Allen JL, Constable PM, et al. Attitudes and roles of general practitioners in the treatment of schizophrenia compared with community mental health staff and patients. Soc Psychiatry Psychiatr Epidemiol. 2004;39(1):78–84. https://doi.org/10.1007/s00127-004-0703-2.CrossRefPubMed

81.

Dalkin SM, Greenhalgh J, Jones D, Cunningham B, Lhussier M. What’s in a mechanism? Development of a key concept in realist evaluation. Implement Sci. 2015;10(1):1–7.CrossRef

82.

Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. Patient Educ Couns [Internet]. 2014;94(3):291–309. Available from:. https://doi.org/10.1016/j.pec.2013.10.031.CrossRef

83.

Annamalai A, Tek C. An overview of diabetes Management in Schizophrenia Patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol. 2015;2015:1–8. https://doi.org/10.1155/2015/969182.CrossRef

84.

Happell B, Manias E, Rope C. Wanting to be heard: mental health consumers' experience of information about medication. Int J Ment Health Nurs. 2004;13(4):242–8.

85.

Happell B, Platania-Phung C, Scott D. Proposed nurse-led initiatives in improving physical health of people with serious mental illness: a survey of nurses in mental health. J Clin Nurs. 2014;23(7–8):1018–29. https://doi.org/10.1111/jocn.12371.CrossRefPubMed

86.

Corrigan P. How stigma interferes with mental health care. Am Psychol. 2004;59(7):614–25. https://doi.org/10.1037/0003-066X.59.7.614.CrossRefPubMed

87.

Pedley R, McWilliams C, Lovell K, Brooks H, Rushton K, Drake RJ, et al. Qualitative systematic review of barriers and facilitators to patient-involved antipsychotic prescribing. BJPsych Open. 2018;4(1):5–14. https://doi.org/10.1192/bjo.2017.5.CrossRefPubMedPubMedCentral

88.

Burton A, Osborn D, Atkins L, Michie S, Gray B, Stevenson F, et al. Lowering cardiovascular disease risk for people with severe mental illnesses in primary care: a focus group study. PLoS One. 2015;10(8):1–16.CrossRef

89.

Pendleton D. The consultation: an approach to learning and teachingle. Oxford University Press; 1984.

90.

Brekke JS, Prindle C. Sung woo Bae, long JD. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv. 2001;52(10):1358–66. https://doi.org/10.1176/appi.ps.52.10.1358.CrossRefPubMed

91.

Carr VJ. The role of the general practitioner in the treatment of schizophrenia: specific issues. Med J Aust. 1997;166(3):143–6. https://doi.org/10.5694/j.1326-5377.1997.tb140048.x.CrossRefPubMed

92.

Bindman J, S. J, S. W, G. S, P. B, E. K. Integration between primary and secondary services in the care of the severely mentally ill: Patients’ and general practitioners’ views. Br J Psychiatry [Internet]. 1997;171(AUG.):169–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9337955.

Title: The role of trust and hope in antipsychotic medication reviews between GPs and service users a realist review
Authors: L. M. Grünwald
C. Duddy
R. Byng
N. Crellin
J. Moncrieff
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Schizophrenia
Care
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03355-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of trust and hope in antipsychotic medication reviews between GPs and service users a realist review

Abstract

Background

Aim

Design & setting

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim

Design & setting

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Cortical haemodynamic response during the verbal fluency task in patients with bipolar disorder and borderline personality disorder: a preliminary functional near-infrared spectroscopy study

Duration of basic and attenuated-psychotic symptoms in individuals at clinical high risk for psychosis: pattern of symptom onset and effects of duration on functioning and cognition

Development of Chinese mental health first aid guidelines for assisting a person affected by a traumatic event: a Delphi expert consensus study

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review

Common mental disorders among seasonal migrant farmworkers in Northwest Ethiopia